Aria

What Aria does

Aria (legal entity: DCENTRIC HEALTH LTD, incorporated in Cyprus) operates a cloud-based real-world evidence (RWE) platform that enables research teams to launch clinical studies in under 48 hours, compared to a stated industry standard of approximately six months. The platform automates the full participant journey — from smartphone onboarding and digital eConsent to real-time ePRO data capture, AE/symptom reporting, medication adherence tracking, and rewards-based engagement — within a single unified study flow hosted on AWS. Its core technical differentiator is an AI-driven Clinical/Roadmap Engine that generates validated study protocol blueprints within 24 hours of submission, combined with a pre-configured study environment that is built while ethics review is still pending. The platform also implements a blockchain-based Right to Be Forgotten mechanism, in which destroying the private key renders encrypted health data non-identifiable to satisfy GDPR Article 17 obligations.

Aria serves four primary customer segments: supplement and nutraceutical companies seeking evidence for health claims, health innovators (digital health and medtech firms) requiring real-world validation, patient organisations running registry and observational studies, and academic research institutes conducting investigator-initiated and multi-site research. GTM combines a product-led growth motion via a free Study Blueprint lead-generation tool with sales-assisted enterprise engagement through Calendly-booked discovery calls. The company maintains institutional partnerships with EIT Health, the European Innovation Council, The Lancet, Novartis Biome, German Medical Institute, and Forbes, which provide credibility and distribution into EU-funded research communities. Pricing is quote-based and not publicly disclosed; revenue appears to derive from subscription or per-study fees for platform access, supplemented by professional services for protocol design and ethics submission packaging.

In May 2026, Aria was acquired by Inventurus Knowledge Solutions, with the acquirer citing Aria's proprietary ontology and niche talent to enhance AI-driven care management workflows. As of the input data, Aria has 1–10 employees, $100,000 of disclosed funding (from Brinc in August 2023), and no publicly disclosed revenue. The platform is described as trusted by EU-backed research teams and international medical institutes, but no named enterprise customer logos or case studies are publicly available.

Name

Aria

Legal name

DCENTRIC HEALTH LTD

Website

https://myaria.health

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

Aria is a Cyprus-based real-world evidence platform that enables research teams to launch clinical studies in under 48 hours via an AI-driven Clinical Engine, serving supplement companies, health innovators, patient organisations, and research institutes. The company was acquired by Inventurus Knowledge Solutions in May 2026.

Ownership category

akta.pro rank

Product category

Clinical Study Infrastructure Software

NAICS

Computer Systems Design and Related Services (54151), Computer Systems Design Services (541512)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Prepackaged Software (7372)

akta.pro primary industry

eCOA/ePRO/eDiary & Patient-Facing Data Collection (HLACAOAB)

akta.pro secondary industries

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Decentralized & Hybrid Trial Site Services (Home Health/Nursing) (HLAGACAH)

Keywords

• Clinical study platform
• Real-world evidence
• Decentralized clinical trials
• Health data infrastructure
• Digital eConsent

Headquarters

HQ city

Limassol

HQ country

Cyprus

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Subscription Recurring: Aria appears to derive revenue from subscription or per-study fees for access to its clinical study platform. The platform automates the full participant journey for real-world evidence studies. Revenue is likely recurring per study or through annual platform subscriptions for research institutes and health innovators that run multiple studies. The 'Get My Study Blueprint' free tool suggests a lead-generation mechanism feeding into paid study platform access.
2. Professional Services: Professional services for study protocol design, ethics submission pack generation (IRB/Ethics documentation), and study setup validation are bundled with platform access. Study-specific customisation and expert review components suggest a services component.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Aria provides a cloud-based real-world evidence and clinical study infrastructure platform that enables research teams to launch decentralised clinical studies within 48 hours of protocol approval. It automates the full participant journey from smartphone onboarding through ePRO/survey delivery, AE/symptoms capture, adherence tracking, and real-time data synchronization on a single unified platform, bundling regulatory-grade GDPR-compliant data handling, blockchain-implemented Right to Be Forgotten, and AI-generated study protocol blueprints (via the Roadmap/Clinical Engine).

Product overview

Aria provides a unified clinical study infrastructure platform comprising three integrated components: the Aria Research Platform (core web-based platform for study setup, oversight, and data management), the My Aria mobile app (participant-facing application for study engagement and health data management), and the Study Blueprint/Roomdmap Engine (automated protocol builder that accelerates study design). The platform is operated by DCENTRIC HEALTH LTD, a Cyprus-registered company, and enables research teams to launch regulatory-grade clinical studies within 48 hours through automated participant journeys, real-time data synchronization, and GDPR-compliant cloud infrastructure built on AWS.

Differentiator

Problem solved

Functional benefit

Products and services

• Aria Research Platform Cloud-based research platform for clinical study setup, real-time participant progress tracking, digital eConsent, smart scheduling, and regulatory-grade data handling. Enables research teams to launch studies within 48 hours of protocol finalization and is designed for supplement/nutraceutical companies, health innovators, patient organisations, and research institutes running decentralised real-world evidence studies.
• My Aria App Mobile application enabling participants to securely view and manage health data from connected healthcare providers and smart devices, participate in research studies, complete surveys and ePROs, report adverse events and symptoms, track medication adherence, manage study tasks and notifications, and earn rewards for participation. Designed for participants in real-world evidence studies.
• Study Blueprint / Roadmap Engine Automated study protocol builder that generates study protocol drafts and identifies key clinical considerations within 24 hours, combining algorithmic generation from Aria's AI Clinical Engine with expert human review. Delivered free of charge as a no-commitment lead-generation tool that converts researchers into paying platform customers.

Quantifiable outcome

• Study launch time reduced from 6 months to under 48 hours
• +3 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Six partnerships are on record, tiered core and minor.

• EIT HealthcoreStrategic or Co-development PartnerEIT Health is listed as a vetted partner on Aria's homepage alongside other high-profile health organisations. EIT Health is a European Union-backed network of leading health companies, universities, and research institutes. The partnership provides Aria with credibility within the European health innovation ecosystem and access to EU-funded research teams as potential customers.
• European Innovation Council (EIC)coreStrategic or Co-development PartnerListed as a vetted partner on Aria's homepage. The European Innovation Council funds and supports European deeptech and health innovators. The association with EIC signals regulatory credibility and alignment with EU research funding priorities, helping Aria reach research institutes and innovators seeking EU-backed validation.
• The LancetminorGTM or Marketing PartnerThe Lancet—one of the world's most prestigious medical journals—is listed among Aria's vetted and partnered organisations. This appears to be a credibility/endorsement association rather than a formal commercial partnership. The presence of The Lancet's logo signals to researchers and institutes that evidence generated on Aria's platform is journal-quality.
• Novartis BiomeminorStrategic or Co-development PartnerListed as a vetted partner. Novartis Biome is Novartis's open innovation platform for health tech collaborations. The partnership signals Aria's ability to serve pharmaceutical and life sciences customers and potentially participate in Novartis's innovation ecosystem.
• German Medical InstituteminorStrategic or Co-development PartnerListed as a vetted partner alongside major European health institutions. The German Medical Institute (likely referencing a German academic or clinical institution) association provides Aria with credibility in the DACH region's research community and potential access to German healthcare data ecosystems.
• ForbesminorGTM or Marketing PartnerListed as a vetted and partnered organisation alongside The Lancet and EU institutions. Forbes is listed as a media/exposure partner, suggesting Aria may have been featured in Forbes coverage or has an active media relationship that provides press coverage and brand credibility.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Medidata (Dassault Systèmes): Industry-leading eCOA/EDC/CTMS platform serving global pharma and CROs. Directly comparable as a clinical-trial infrastructure vendor; Aria competes on speed and decentralized workflows while Medidata dominates on enterprise-grade validation.
• Veeva Systems: Cloud life-sciences platform with CTMS, eTMF, and study-startup offerings. Comparable as an enterprise clinical-operations vendor; Aria is a more decentralized, AI-automated alternative aimed at smaller sponsors.
• Oracle Clinical One: Oracle's unified clinical-trial platform (EDC, RTSM, ePRO). Comparable as an enterprise clinical trial infrastructure competitor with regulatory-grade validation depth Aria lacks.
• Citeline (Pharmaprojects / Sitetrove): Clinical trial intelligence and study-design data provider used by pharma R&D planning. Comparable adjacent player supplying study-design and feasibility inputs that complement Aria's protocol-generation workflow.

Direct peers

• Castor: Decentralized clinical trial platform offering eCRF, ePRO, eConsent, and remote data capture. Closely comparable on product scope (ePRO, eConsent, decentralized study setup) and on serving academic and emerging-sponsor customers.
• Medable: Decentralized clinical trial platform with patient apps, eCOA, eConsent, and telehealth modules. Directly comparable as a decentralized ePRO/eConsent platform targeting pharma and health innovators.
• Clinical Ink: eCOA/ePRO and patient-engagement platform for clinical trials. Directly comparable on patient-facing data collection and ePRO/eDiary functionality that anchors Aria's primary category.
• Science 37: Decentralized clinical trial operator with patient-facing mobile platform and Metasite telehealth. Comparable as a decentralized-study infrastructure player pursuing the same buyer pain Aria targets.
• ObvioHealth: Decentralized clinical trial platform with patient app, ePRO, and remote-monitoring workflows. Comparable mid-sized decentralized-trial peer serving supplement and emerging-sponsor segments similar to Aria's.

Emerging players

• Trialbee: Patient-recruitment and real-world-data platform for clinical trials. Comparable as an emerging digital infrastructure player targeting sponsors seeking faster, evidence-grade study operations.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/myariahealth
• Facebookfacebook.com/myaria.health

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds4 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aria